INTRODUCTION
Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease. Cytogenetic and/or molecular studies are used to assign 30-40% of AML cases carrying specific genetic lesions [e.g. t(15;17), t(8; 21) or Inv16], to different prognostic subgroups, to monitor minimal residual disease and to select patients who could benefit from targeted therapies 1 . However, they cannot be applied to 40-50% of AML patients that at conventional cytogenetics exhibit a normal karyotype 1, 2 . We recently found exon-12 nucleophosmin (NPM) gene mutations in approximately 60% AML with normal karyotype (about one-third of all adult AML) that are characterized by distinct morphological, phenotypic and molecular features 3 , as well as distinct gene expression profile signature 4 . NPM mutations predict good response to induction therapy and favourable prognosis [5] [6] [7] [8] , and could serve to monitor minimal residual disease 9 . Thus, analysis of NPM mutations emerges as a major, new step in the diagnostic/prognostic work-up of AML patients with a normal karyotype.
Reverse-transcriptase polymerase chain reaction (RT-PCR), mutational analysis or gene expression profiling, are usually employed for detecting genetic abnormalities or specifically over-expressed genes with diagnostic/prognostic significance. However, demand is growing for simple, inexpensive, and specific immunological tests 10 that can serve as a surrogate to, or used in integration with, molecular studies. Examples include immunohistochemical detection of proteins like anaplastic lymphoma kinase (ALK) in CD30+ anaplastic large cell lymphoma 10 expression of NPM, a multifunctional [15] [16] [17] [18] [19] [20] nucleo-cytoplasmic shuttling protein 21 with restricted nucleolar localization 10, 22 , closely correlates with exon-12 NPM mutations 3 . To validate these observations, the present study determined, whether immunostaining for NPM in paraffin-embedded biopsies reliably predicts all exon-12 NPM mutations in a large cohort of adult AML patients (n=450) from the GIMEMA/AML12 EORTC trial. In a few cases, we investigated the mechanism of altered nucleo-cytoplasmic traffic of wild-type and mutated NPM in primary AML cells.
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MATERIALS AND METHODS

Case population
We selected bone marrow or peripheral blood samples from 450 adult AML patients (age ) that were enrolled in the GIMEMA LAM99P/AML12 EORTC trial. Seventy of the 450 patients were previously reported by the authors 3 . Inclusion criteria were provision of full information on subcellular expression of the NPM protein and NPM gene mutational status. Written informed consent to examine leukemic samples was obtained at each participating center.
Analysis of NPM mutations in leukemic samples
Exon-12 NPM mutations were analyzed by direct sequencing, as previously described 3 or using DHPLC (Wave TM System, Transgenomic Inc., Omaha, Nebraska; USA) 23 .
Antibodies
The value of immunohistochemistry in predicting exon-12 NPM mutations was assessed through detection of aberrant NPM cytoplasmic expression in leukemic cells. We immunostained 450 AML samples with mouse anti-NPM monoclonal antibodies (clones 322 and 376) which are suitable for detecting NPM in paraffin embedded sections 22 . These antibodies recognize both the wild-type NPM and the NPM leukemic mutants.
In selected NPMc+ AML cases, we used specifically directed antibodies to investigate by Western blot and co-immunoprecipitation the subcellular distribution of NPM leukemic mutants without interference of wild-type NPM (and vice versa) and to assess whether mutant and wild-type NPM proteins physically interact. NPM leukemic mutants were detected using a rabbit affinity-purified polyclonal antibody (Sil-C) generated against only. Dry cell pellets were snap-frozen in liquid nitrogen. Frozen pellets were thawed and lysed in hypotonic buffer using the slightly modified method of Schreiber et al. 26 . The supernatant was saved as cytoplasmic fraction. The pellet fraction, containing nuclei, was washed with hypotonic buffer and dissolved in hypertonic buffer. After centrifugation, the only.
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Equivalent dilutions (representing equal number of cells) of cytoplasmic, nuclear or insoluble fractions were prepared for Western blot analysis of endogenous NPM mutant protein distribution using Sil-C, the specific anti-NPM mutant antibody.
To test whether wild-type and mutant NPM proteins interact with each other and with Crm1/Exportin-1, co-immunoprecipitation experiments were performed on leukemic cell lysates from NPMc+ and NPMc-AML patients, with OCI/AML3 cell line as control.
Cell lysates were prepared as previously described 24 , incubated with 2 µg of either control only.
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RESULTS
Exon-12 NPM mutations cause similar alterations at C-terminus of NPM mutants
NPM mutations were detected in 200/450 AML cases (44.4%) ( Table 1 ). The frequency was higher than the expected 35% in adult AML as detected by cytoplasmic dislocation of NPM 3 , because of case selection bias. In fact, DNA or RNA for NPM mutational analysis was more frequently available in patients with normal karyotype (often associated with NPM mutations) than in those carrying other genetic abnormalities.
All NPM-mutated AMLs were heterozygous and retained a wild-type allele. Fourteen NPM mutations were identified ( Table 2 ). Besides the original mutations A to F 3 , we detected eight new exon-12 NPM mutation variants, named J to Q ( Table 2) . Seven (J to P) are reported here for the first time. Mutation Q corresponds to mutation Mm, as described by Schnittger et al. 6 Confirming our original findings 3 , type A mutation, a TCTG insertion/duplication between position nt 960 and 961, was the most common variant (80.5% of cases) followed by mutation B (7.5%) and mutation D (5.5%). Other NPM mutations occurred rarely.
Despite DNA heterogeneity, all NPM mutations resulted in similar alterations at the C-terminus of the predicted mutant proteins, i.e. a new leucine-rich nuclear export signal (NES) motif 27 ( Table 2 , violet) and mutated tryptophans 288 and 290 (or tryptophan 290 alone) 24 . The most frequent NES motif (L-xxx-V-xx-V-x-L) was present in 7/14 (50.0%) NPM leukemic mutants. Other mutants carried a NES motif with another hydrophobic amino acid replacing valine at the second position (Table 2 ). In particular, 5/14 mutants (35.7%) carried the L-xxx-L-xx-V-x-L motif; 1/14 mutants (7.1%) ( Table 2; mutation O) displayed the L-xxx-F-xx-V-x-L motif; and 1/14 mutants (7.1%) ( 24 , the most frequent NES motif (L-xxx-V-xx-V-x-L) was associated with mutations of both tryptophans 288 and 290. Tryptophan 288 was retained only in NPM mutants carrying variants of the most common NES motif, i.e. leucine, phenylalanine or methionine instead of valine at the second position (mutants O and Q).
Immunohistochemistry predicts all exon-12 NPM gene mutation variants
The results of the immunohistochemical studies are shown in Table 1 . Expression of NPM was cytoplasmic (NPMc+) in 200 cases, all carrying NPM exon-12 mutations.
NPM immunoreactivity in bone marrow trephines and cell pellets was comparable.
Cytoplasmic NPM was predominantly observed in M4 and M5 categories. NPM expression was nucleus-restricted (NPMc-) in 250 AML cases, all carrying wild-type NPM gene. All 
NPM cytoplasmic accumulation in primary NPMc+ AML is NES-dependent
In transfected cells, cytoplasmic accumulation of NPM mutants depends both on a new NES motif and mutated tryptophan(s) at the C-terminus of leukemic mutants 24 . To assess whether NES-dependent nuclear export of NPM operates in primary AML cells, we only.
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Incubation with LMB relocated cytoplasmic wild-type NPM into the insoluble nuclear fraction, reducing the protein in the other compartments (Figure 2A , compare lanes 7-9
with lanes 1-3). , confirm that mutations at exon-12 of the NPM gene are heterogeneous, it remains a mystery why these mutations occur at such a high frequency in, and are so specific to, AML.
Here we report a perfect correlation between cytoplasmic expression of NPM and the presence of exon-12 NPM mutations. This immunohistochemical finding is consistent with the presence at the C-terminus of all 14 NPM mutant proteins of a new NES motif 27 and mutated tryptophans 288 and 290 (or tryptophan 290 alone). In fact, in transfected cells, these molecular alterations are both crucial for aberrant NPM mutant export from nucleus to cytoplasm 24 . In primary AML cells, the role of carboxy-terminus mutated tryptophan(s) in NPM cytoplasmic accumulation is difficult to demonstrate experimentally.
However, the role of the NES motif in aberrant NPM nuclear export can be addressed using LMB, a specific inhibitor of Crm1, the receptor for protein nuclear export in yeast and mammalian cells 28 In addition to the mutations described in this study, NPM cytoplasmic dislocation has been also reported by Thiede at al. 8 in association with exon-12 NPM mutations termed DD-1, DD-3, DD-4 and DD-9. Unfortunately, no immunohistochemical data on NPM subcellular localization are available for the other exon-12 NPM mutation variants that have been reported to date [5] [6] [7] [30] [31] [32] . However, all leukemic NPM mutants in those reports carried a new NES and mutated tryptophan(s) at their C-terminus. Thus, it is reasonable to assume that, as in the present study, immunohistochemistry would detect NPM mutant proteins as cytoplasmic-dislocated and serve as a highly specific predictor of exon-12 NPM mutations.
Immunostaining for NPM is another example of how a leukemia-specific genetic lesion may be identified by investigating localization of altered gene products. A similar approach in acute promyelocytic leukemia is the immunocytological detection of t (15;17) through visualization of wild-type PML protein delocalization from nuclear bodies to microspeckels which is mediated by the chimeric PML-RARα protein 10, 14 .
As NPM protein is not reliably detected in smears and cytospins 3, 22 , we recommend immunostaining bone marrow biopsy samples, although paraffin-embedded bone marrow clots 33 or leukemic cell pellets are valid alternatives. Given its low cost and high specificity, the NPM immunohistochemical test seems ideal for centers that are not equipped for molecular screening and do not have highly specialized personnel.
In state-of-the-art centers, it might configure as the first step in the differential characterization of AML by molecular and genetic studies. A proposal of how the immunohistochemical test could be utilized for this purpose is shown in Figure 3 . In NPMc-AML molecular/cytogenetics analyses are mandatory for detecting major recurrent changes, eg. t(15;17), t(8;21), inv16, t(6;9), and 11q23/MLL rearrangements. In NPMc+ AML, they can be avoided since they do not concur with cytoplasmic NPM 3 . In approximately 14% of NPMc+ AMLs with minor chromosomal abnormalities help pick-up rare changes with potential prognostic significance. NPM mutational analysis is unnecessary in NPMc-AML but should be performed in samples of NPMc+ AML ( Figure   3 ) since it can serve as a marker for monitoring minimal residual disease in AML patients with a normal karyotype 9 . FLT3 gene mutations 34 should be sought since their correlation with cytoplasmic/mutated NPM help identify new prognostic subgroups in AML with normal karyotype [5] [6] [7] [8] . Validation of the integrated NPM-based immuno-histochemical-cytogeneticmolecular approach to AML characterization in large multicenter trials is warranted.
In routine diagnostics, when no fresh tissue is available for cytogenetic/molecular studies, e.g. marrow "punctio sicca" or small biopsies such as in skin involvement by myeloid sarcoma 35 , the NPM-based immunohistochemical test is at present the only tool for diagnosing AML carrying NPM exon-12 mutations (NPMc+ AML). When cytogenetics fails because of lack of mitoses, as in 20-40% of AML in multicenter trials, the NPM-based immunohistochemical test can serve to diagnose normal karyotype and absence of recurrent genetic rearrangements. In retrospective screening for NPM mutations in paraffin sections of archived biopsy material from AML patients, the immunohistochemical test can replace molecular biology procedures. Moreover, as immunohistochemistry correlates cytoplasmic expression of NPM (and therefore NPM mutations) with leukemic cell morphology, may be a valuable tool for studying lineage involvement in NPMc+ AML.
Detecting NPM mutations by immunohistochemistry may also impact on the current AML classification because cytoplasmic NPM identifies a type of leukemia with distinct clinicobiological features 3 which, in the WHO classification, would be grouped (given their normal karyotype) under the term "acute myeloid leukemia not otherwise categorized" 36 .
Immunohistochemical detection of NPM mutations is of prognostic value since they appear to be predictors of good response to induction therapy 3, 6 and long term prognosis [5] [6] [7] [8] in AML with normal karyotype. In the future, specific anti-mutant NPM antibodies are expected to play a role in monitoring minimal residual disease. 
